KRAS and non-small cell lung carcinoma: In vitro evidence suggests development of adaptive resistance to the KRAS-G12C inhibitor ARS-1620, the structural precursor to AMG510, in an NSCLC cell line was due to a subpopulation of cells synthesizing new KRAS-G12C proteins, corresponding with increased EGFR signalling and aurora kinase A activation (Xue et al., 2020).